Immunocore Holdings plc - ADR Forecast, price target & analysts
Immunocore Holdings plc - ADR Target price 2025 - Analyst rating & recommendation
Immunocore Holdings plc - ADR Classifications & Recommendation:
Immunocore Holdings plc - ADR Price Target
| Target Price | $65.19 |
| Price | $29.58 |
| Potential |
120.37%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target Immunocore Holdings plc - ADR 2026 .
The average Immunocore Holdings plc - ADR target price is $65.19.
This is
120.37%
register free of charge
$100.00
238.07%
register free of charge
$23.59
20.25%
register free of charge
|
|
| A rating was issued by 16 analysts: 12 Analysts recommend Immunocore Holdings plc - ADR to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Immunocore Holdings plc - ADR stock has an average upside potential 2026 of
120.37%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 310.33 | 356.10 |
| 23.94% | 14.75% | |
| EBITDA Margin | -21.36% | -30.03% |
| 4.09% | 40.60% | |
| Net Margin | -16.45% | -19.61% |
| 27.81% | 19.18% |
15 Analysts have issued a sales forecast Immunocore Holdings plc - ADR 2025 . The average Immunocore Holdings plc - ADR sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Immunocore Holdings plc - ADR EBITDA forecast 2025. The average Immunocore Holdings plc - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Immunocore Holdings plc - ADR Analysts have issued a net profit forecast 2025. The average Immunocore Holdings plc - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.02 | -1.40 |
| 10.53% | 37.25% | |
| P/E | negative | |
| EV/Sales | 3.07 |
6 Analysts have issued a Immunocore Holdings plc - ADR forecast for earnings per share. The average Immunocore Holdings plc - ADR <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Immunocore Holdings plc - ADR stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Immunocore Holdings plc - ADR...
Current Immunocore Holdings plc - ADR Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham | Locked ➜ Locked | Locked | Feb 27 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 27 2025 |
| Needham | Locked ➜ Locked | Locked | Jan 10 2025 |
| Morgan Stanley | Locked ➜ Locked | Locked | Dec 13 2024 |
| Mizuho | Locked ➜ Locked | Locked | Nov 11 2024 |
| Needham | Locked ➜ Locked | Locked | Nov 07 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Oct 24 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 27 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Jan 10 2025 |
|
Locked
Morgan Stanley: Locked ➜ Locked
|
Dec 13 2024 |
|
Locked
Mizuho: Locked ➜ Locked
|
Nov 11 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Nov 07 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Oct 24 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
